# CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT05654779** · PHASE1 · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 4 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** LCAR-AMDR Cells Product

## Key facts

- **NCT ID:** NCT05654779
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-12
- **Primary completion:** 2023-09-26
- **Final completion:** 2023-09-26
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Both the sponsors and collaborator are considering terminating the study
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05654779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05654779, "CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05654779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*